Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773576 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Risperidone Implants
A Phase 3 study of Schizophrenia, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT02773576 is a Phase 3 study of Schizophrenia that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 140 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02773576, a Phase 3 study of Schizophrenia, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
Conditions Studied
Interventions
- DRUG Risperidone implant
Study Locations (1)
California
- Collaborative Neuroscience Network - Garden Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02773576
The ClinicalTrials.gov registry entry for NCT02773576 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (36% lower). The listed sponsor is Braeburn Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Risperidone implant is the first listed.
NCT02773576 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02773576 about?
NCT02773576 is a clinical study titled "Safety and Tolerability of Risperidone Implants". A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
What is the current status of trial NCT02773576?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2016-04. Estimated completion is 2017-09.
What conditions does trial NCT02773576 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02773576?
The interventions under investigation include: Risperidone implant (DRUG).
Who is sponsoring clinical trial NCT02773576?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02773576 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.